Table 1.
Patient characteristic (N = 77)
| Dose rate < 6 cGy/min (N = 23) | Dose rate ≥ 6 cGy/min (N = 54) | P-value | |
|---|---|---|---|
| Age at TBI (year) | 29.4 ± 18.6 (1.9–66.4) | 15.9 ± 8.9 (1.8–41.7) | 0.002b |
| Sex | |||
| Male | 14 (60.9%) | 32 (59.9%) | 0.895a |
| Female | 9 (39.1%) | 22 (40.1%) | |
| Type of Cancer | |||
| ALL | 15 (65.2%) | 32 (59.3%) | 0.172a |
| AML | 2 (8.7%) | 14 (25.9%) | |
| Others | 6 (26.1%) | 8 (14.8%) | |
| Total dose (Gy) | 11.7 ± 0.9 (9–12) | 10.9 ± 1.1 (9–12) | 0.004b |
| Daily dose (Gy) | 3.0 ± 0.1 (2.5–3.0) | 3.1 ± 0.2 (2.3–3.3) | 0.001b |
| Daily dose < 3 | 1 (4.3%) | 2 (3.7%) | |
| Daily dose ≥3 | 22 (95.7%) | 52 (96.3%) | 0.017a |
| Donor type | |||
| Related | 16 (69.6%) | 22 (40.7%) | 0.021a |
| Unrelated | 7 (30.4%) | 32 (59.3%) | |
| Conditioning regimen | |||
| Cyclophosphamide | 4 (17.4%) | 8 (14.8%) | 0.271a |
| Cyclophosphamide + otherc | 14 (60.9%) | 24 (44.4%) | |
| Othersd | 5 (21.7%) | 22 (40.7%) | |
| Number of prior chemotherapy regimens | |||
| 1 | 3 (13.0%) | 14 (25.9%) | 0.193a |
| 2 | 8 (34.8%) | 23 (42.6%) | |
| ≥ 3 | 12 (52.2%) | 17 (31.5%) | |
aP-value by chi-square test. bP-value by Mann-Whitney U test
c Other: cytarabine, fludarabine, etoposide
d Others: cytarabine/fludaraibine, busulfan/fludarabine/etoposide, melphalan, melphalan/fludarabine, thiotepa